Loading...
•
Jun 30, 2022
Trevena Q2 2022 Earnings Report
Trevena reported second quarter 2022 results and provided a business update.
Key Takeaways
Trevena reported a net loss attributable to common stockholders of $15.0 million, or $0.09 per share, for the second quarter of 2022. Cash and cash equivalents were $49.5 million as of June 30, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements to mid-2023.
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study
Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single ascending dose and food effect study segments fully enrolled
TRV045 demonstrated potential antiepileptic effect in multiple preclinical models
Cash balance of $49.5 million at Q2 provides cash runway to mid-2023 with previously announced strategic allocation of resources and cost reductions
Forward Guidance
The Company believes that cash and cash equivalents were sufficient to fund the Company’s operating expenses and capital expenditure requirements to mid-2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...